Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GALR3 | O60755 | 1/20 | 0.44 |
| ▸ | NPY1R | P25929 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4760122 | 0.82 | TSHR (0.47) | CYP19A1SMN1; SMN2L3MBTL1RAB9AGAA | |
| SCHEMBL9304768 | 0.79 | CYP19A1 (0.58) | CYP19A1SMN1; SMN2L3MBTL1RAB9AGAA | |
| SCHEMBL15243034 | 0.77 | CYP19A1 (0.56) | CYP19A1SMN1; SMN2L3MBTL1RAB9AGAA | |
| SCHEMBL2326678 | 0.75 | RAB9A (0.62) | CYP19A1SMN1; SMN2L3MBTL1RAB9AGAA | |
| SCHEMBL17610665 | 0.75 | CYP19A1 (0.53) | CYP19A1SMN1; SMN2L3MBTL1RAB9AGAA | |
| SCHEMBL4834224 | 0.72 | TNF (0.44) | CYP19A1SMN1; SMN2RAB9AGAAKDM4E | |
| SCHEMBL6760656 | 0.71 | CYP19A1 (1.00) | CYP19A1L3MBTL1RAB9APOLBMAPT | |
| SCHEMBL8035242 | 0.71 | SMN1; SMN2 (0.53) | SMN1; SMN2L3MBTL1RAB9AGAAPOLB | |
| SCHEMBL8756843 | 0.71 | ADORA2A (0.53) | CYP19A1SMN1; SMN2L3MBTL1GAAKDM4E | |
| SCHEMBL16856698 | 0.71 | CYP19A1 (0.48) | CYP19A1SMN1; SMN2L3MBTL1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963328-B1 | INHIBITORS OF CYSTEINE PROTEASES, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2013-10-30 | — | — | EP | disclosed |
| US-20090181972-A1 | Novel Inhibitors of Cysteine Proteases, the Pharmaceutical Compositions Thereof and their Therapeutic Applications | HYBRIGENICS SA (FR) | 2009-07-16 | — | — | US | disclosed |
| US-7462615-B2 | Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications | HYBRIGENICS SA (FR) | 2008-12-09 | — | — | US | disclosed |
| EP-1963328-A2 | INHIBITORS OF CYSTEINE PROTEASES, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | Hybrigenics S.A. (FR) | 2008-09-03 | — | — | EP | disclosed |
| EP-1798232-A1 | Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications | Hybrigenics S.A. (FR) | 2007-06-20 | — | — | EP | disclosed |
| EP-1798232-A1 | Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications | Hybrigenics S.A. (FR) | 2007-06-20 | — | — | EP | disclosed |
| WO-2007066200-A2 | INHIBITORS OF CYSTEINE PROTEASES, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007066200-A2 | INHIBITORS OF CYSTEINE PROTEASES, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2007-06-14 | — | — | WO | disclosed |
| US-20070135439-A1 | Novel inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications | HYBRIGENICS SA (FR) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135439-A1 | Novel inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications | SERPINB1, CTSF, CTSE | CYP19A1 2944/4885SMN1; SMN2 4147/4885L3MBTL1 4127/4885 |
| US-20090181972-A1 | Novel Inhibitors of Cysteine Proteases, the Pharmaceutical Compositions Thereof and their Therapeutic Applications | SERPINB1, CTSF, CTSE | CYP19A1 2944/4885SMN1; SMN2 4147/4885L3MBTL1 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.